1
|
Paul SM, Yohn SE, Popiolek M, Miller AC, Felder CC. Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia. Am J Psychiatry 2022; 179:611-627. [PMID: 35758639 DOI: 10.1176/appi.ajp.21101083] [Citation(s) in RCA: 32] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Schizophrenia remains a challenging disease to treat effectively with current antipsychotic medications due to their limited efficacy across the entire spectrum of core symptoms as well as their often burdensome side-effect profiles and poor tolerability. An unmet need remains for novel, mechanistically unique, and better tolerated therapeutic agents for treating schizophrenia, especially those that treat not only positive symptoms but also the negative and cognitive symptoms of the disease. Almost 25 years ago, the muscarinic acetylcholine receptor (mAChR) agonist xanomeline was reported to reduce psychotic symptoms and improve cognition in patients with Alzheimer's disease. The antipsychotic and procognitive properties of xanomeline were subsequently confirmed in a small study of acutely psychotic patients with chronic schizophrenia. These unexpected clinical findings have prompted considerable efforts across academia and industry to target mAChRs as a new approach to potentially treat schizophrenia and other psychotic disorders. The authors discuss recent advances in mAChR biology and pharmacology and the current understanding of the relative roles of the various mAChR subtypes, their downstream cellular effectors, and key neural circuits mediating the reduction in the core symptoms of schizophrenia in patients treated with xanomeline. They also provide an update on the status of novel mAChR agonists currently in development for potential treatment of schizophrenia and other neuropsychiatric disorders.
Collapse
|
2
|
Khadernaick AB, Kumar GS, Sandhya P, Bhikshapathi D. A Highly Sensitive LC–MS/MS Method Development and Validation of Fedratinib in Human Plasma and Pharmacokinetic Evaluation in Healthy Rabbits. CURR PHARM ANAL 2021. [DOI: 10.2174/1573412916999200512121023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
A simple and sensitive quantitation analytical technique by liquid chromatography–tandem mass
spectrometry (LC-MS/MS) is essential for fedratinib in biological media with kinetic study in healthy rabbits.
Objective:
The main objectives of the present research work are to LC-MS/MS method development and validate procedure
for the quantitation of fedratinib and its application to kinetic study in rabbits.
Methods:
Separation of processed samples were employed on zorbax SB C18 column (50mm×4.6 mm) 3.5µm with a movable
phase of methanol, acetonitrile and 0.1% formic acid in the ratio of 30:60:10. The movable phase was monitored through
column at 0.8 ml/min flow rate. The drug and ibrutinib internal standard (IS) were evaluated by monitoring the transitions of
m/z -525.260/57.07 and 441.2/55.01 for fedratinib and IS respectively in multiple reaction monitoring mode.
Results:
The linear equation and coefficient of correlation (R2) results were y =0.00348x+0.00245 and
0.9984, respectively. Intra and inter-day precision RSD findings of the developed technique were
found in the range of 2.4 - 5.3% for the quality control (QC)-samples (252.56, 1804.0 and 2706 ng/ml).
The proposed method was subjected to pharmacokinetic study in healthy rabbits and the kinetic study,
fedratinib showed mean AUClast 13190±18.1 hr*ng/ml and Cmax was found to be 3550±4.31 ng/ml in
healthy rabbits.
Conclusion:
The validated method can be applicable for the pharmacokinetic and toxicokinetic studies in the clinical and
forensic analysis of fedratinib in different kinds of biological matrices successfully.
Collapse
Affiliation(s)
| | | | - Pamu Sandhya
- Department of Pharmaceutics, Shadan Women’s college of Pharmacy, Hyderabad, India
| | | |
Collapse
|
3
|
Ravi Y, Bhikshapathi D, Cheruku S, Rajkamal B. Development of Fast and Simple LC-ESI-MS/MS Technique for the Quantification of Regorafenib; Application to Pharmacokinetics in Healthy Rabbits. CURR PHARM ANAL 2021. [DOI: 10.2174/1573412916666191111144707] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
A simple quantification technique by liquid chromatography electrospray ionization-
tandem mass spectrometry (LC-ESI-MS/MS) is required for regorafenib in biological matrices
with bioavailability studies in healthy rabbits, when compared with reported techniques.
Objective:
The main aim of the research work was to develop a validated LC-ESI-MS/MS technique
for the quantification of regorafenib and application to bioavailability studies in healthy rabbits.
Methods:
Chromatographic separation was achieved with hypersil-C18 analytical column (50mm×4.6 mm,
4μm) and mobile phase composition of acetonitrile and 5mM ammonium acetate in the proportion of
70:30. The mobile phase was infused into the column with high pressure to get a 0.7 ml/min flow rate.
The total retention time of the analyte is promising when compared with the existed methods for
regorafenib. Quantitation was processed by monitoring transitions of m/z -483.0/262.0 and 450.0/260.0
for regorafenib and internal standard respectively in multiple reaction monitoring.
Results:
The linearity equation and correlation coefficient (R2) findings were y =0.9948x+2.6624 and
0.998 respectively. The intra and inter-day precision of the developed technique was found between
1.00 – 8.50% for the QC-samples (2, 4, 240 and 480ng/ml). From bioavailability study, the drug was
shown Tmax of 3.688 ± 0.754; average AUC0→α and AUC0→t were 6476.81 ± 259.59 and 6213.845 ±
257.892 respectively and Cmax was found to be 676.91 ± 22.045 in healthy rabbits.
Conclusion:
The developed technique was validated and successfully applied in the pharmacokinetic
study of the drug (40 mg tablet) administered through the oral route in healthy rabbits.
Collapse
Affiliation(s)
- Yatha Ravi
- Department of Pharmacy, Mewar University, Chittorgarh, Rajasthan,India
| | | | - Shankar Cheruku
- Department of Pharmaceutical Analysis, Vijaya College of Pharmacy, Hyderabad,India
| | - Bigala Rajkamal
- Department of Pharmacy, Mewar University, Chittorgarh, Rajasthan,India
| |
Collapse
|
4
|
Abstract
Xanomeline (1) is an orthosteric muscarinic acetylcholine receptor (mAChR) agonist, often referred to as M1/M4-preferring, that received widespread attention for its clinical efficacy in schizophrenia and Alzheimer's disease (AD) patients. Despite the compound's promising initial clinical results, dose-limiting side effects limited further clinical development. While xanomeline, and related orthosteric muscarinic agonists, have yet to receive approval from the FDA for the treatment of these CNS disorders, interest in the compound's unique M1/M4-preferring mechanism of action is ongoing in the field of chemical neuroscience. Specifically, the promising cognitive and behavioral effects of xanomeline in both schizophrenia and AD have spurred a renewed interest in the development of safer muscarinic ligands with improved subtype selectivity for either M1 or M4. This Review will address xanomeline's overall importance in the field of neuroscience, with a specific focus on its chemical structure and synthesis, pharmacology, drug metabolism and pharmacokinetics (DMPK), and adverse effects.
Collapse
Affiliation(s)
- Aaron M. Bender
- Vanderbilt
Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
| | - Carrie K. Jones
- Vanderbilt
Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
- Department
of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
| | - Craig W. Lindsley
- Vanderbilt
Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
- Department
of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
- Department
of Chemistry, Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232, United States
| |
Collapse
|
5
|
Ma Y, Kiesewetter DO, Lang L, Gu D, Chen X. Applications of LC-MS in PET radioligand development and metabolic elucidation. Curr Drug Metab 2011; 11:483-93. [PMID: 20540692 DOI: 10.2174/138920010791636167] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2010] [Accepted: 05/11/2010] [Indexed: 11/22/2022]
Abstract
Positron emission tomography (PET) is a very sensitive molecular imaging technique that when employed with an appropriate radioligand has the ability to quantititate physiological processes in a non-invasive manner. Since the imaging technique detects all radioactive emissions in the field of view, the presence and biological activity of radiolabeled metabolites must be determined for each radioligand in order to validate the utility of the radiotracer for measuring the desired physiological process. Thus, the identification of metabolic profiles of radiolabeled compounds is an important aspect of design, development, and validation of new radiopharmaceuticals and their applications in drug development and molecular imaging. Metabolite identification for different chemical classes of radiopharmaceuticals allows rational design to minimize the formation and accumulation of metabolites in the target tissue, either through enhanced excretion or minimized metabolism. This review will discuss methods for identifying and quantitating metabolites during the pre-clinical development of radiopharmaceuticals with special emphasis on the application of LC/MS.
Collapse
Affiliation(s)
- Ying Ma
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of health (NIH), Bethesda, MD 20892, USA
| | | | | | | | | |
Collapse
|
6
|
Reid AE, Ding YS, Eckelman WC, Logan J, Alexoff D, Shea C, Xu Y, Fowler JS. Comparison of the pharmacokinetics of different analogs of 11C-labeled TZTP for imaging muscarinic M2 receptors with PET. Nucl Med Biol 2008; 35:287-98. [PMID: 18355684 DOI: 10.1016/j.nucmedbio.2008.01.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2007] [Revised: 01/03/2008] [Accepted: 01/06/2008] [Indexed: 11/28/2022]
Abstract
INTRODUCTION The only radiotracer available for the selective imaging of muscarinic M2 receptors in vivo is 3-(3-(3-[18F]fluoropropyl)thio)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine) ([18F]FP-TZTP). We have prepared and labeled 3-(3-(3-fluoropropylthio)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridne (FP-TZTP, 3) and two other TZTP derivatives with 11C at the methylpyridine moiety to explore the potential of using 11C-labeled FP-TZTP for positron emission tomography imaging of M2 receptors and to compare the effect of small structural changes on tracer pharmacokinetics (PK) in brain and peripheral organs. METHODS 11C-radiolabeled FP-TZTP, 3-(3-propylthio)-TZTP (6) and 3,3,3-(3-(3-trifluoropropyl)-TZTP (10) were prepared, and log D, plasma protein binding (PPB), affinity constants, time-activity curves (TACs), area under the curve (AUC) for arterial plasma, distribution volumes (DV) and pharmacological blockade in baboons were compared. RESULTS Values for log D, PPB and affinity constants were similar for 3, 6 and 10. The fraction of parent radiotracer in the plasma was higher and the AUC lower for 10 than for 3 and 6. TACs for brain regions were similar for 3 and 6, which showed PK similar to the 18F tracer, while 10 showed slower uptake and little clearance over 90 min. DVs for 3 and 6 were similar to the 18F tracer but higher for 10. Uptake of the three tracers was significantly reduced by coinjection of unlabeled 3 and 6. CONCLUSION Small structural variations on the TZTP structure greatly altered the PK in brain and behavior in blood with little change in the log D, PPB or affinity. The study suggests that 11C-radiolabeled 3 will be a suitable alternative to [18F]FP-TZTP for translational studies in humans.
Collapse
Affiliation(s)
- Alicia E Reid
- Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA.
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Valaskovic GA, Utley L, Lee MS, Wu JT. Ultra-low flow nanospray for the normalization of conventional liquid chromatography/mass spectrometry through equimolar response: standard-free quantitative estimation of metabolite levels in drug discovery. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2006; 20:1087-96. [PMID: 16506151 DOI: 10.1002/rcm.2414] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Nanospray experiments were performed on an ensemble of drug molecules and their commonly known metabolites to compare performance with conventional electrospray ionization (ESI) and to evaluate equimolar response capabilities. Codeine, dextromethorphan, tolbutamide, phenobarbital, cocaine, and morphine were analyzed along with their well-known metabolites that were formed via hydroxylation, dealkylation, hydrolysis, and glucuronidation. Nanospray exhibited a distinct trend toward equimolar response when flow rate was reduced from 25 nL/min to less than 10 nL/min. A more uniform response between the parent drug and the corresponding metabolites was obtained at flow rates of 10 nL/min or lower. The largest discrepancy was within +/-50% for plasma samples. Nanospray was used as a calibrator for conventional ESI liquid chromatography/tandem mass spectrometry (LC/MS/MS) and normalization factors were applied to the quantitation of an acyl-glucuronide metabolite of a proprietary compound in rat plasma. A nanospray calibration method was developed with the standard curve of the parent drug to generate quantitative results for drug metabolites within +/-20% of that obtained with reference standards and conventional ESI. The nanospray method provides a practical solution for the quantitative estimation of drug metabolites in drug discovery when reference standards are not available.
Collapse
MESH Headings
- Calibration/standards
- Chromatography, Liquid/instrumentation
- Chromatography, Liquid/methods
- Chromatography, Liquid/standards
- Drug Design
- Drug Evaluation, Preclinical/instrumentation
- Drug Evaluation, Preclinical/methods
- Equipment Design
- Equipment Failure Analysis
- Flow Injection Analysis/methods
- Flow Injection Analysis/standards
- Microfluidics/instrumentation
- Microfluidics/methods
- Microfluidics/standards
- Nanotechnology/instrumentation
- Nanotechnology/methods
- Nanotechnology/standards
- Pharmaceutical Preparations/analysis
- Pharmaceutical Preparations/metabolism
- Reference Values
- Spectrometry, Mass, Electrospray Ionization/instrumentation
- Spectrometry, Mass, Electrospray Ionization/methods
- Spectrometry, Mass, Electrospray Ionization/standards
Collapse
|
8
|
Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS DRUG REVIEWS 2003; 9:159-86. [PMID: 12847557 PMCID: PMC6741650 DOI: 10.1111/j.1527-3458.2003.tb00247.x] [Citation(s) in RCA: 105] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Binding studies initially suggested that the muscarinic agonist, xanomeline, was a subtype selective muscarinic M(1) receptor agonist, and a potential new treatment for Alzheimer's disease. However, later in vitro and in vivo functional studies suggest that this compound is probably better described as a subtype selective M(1)/M(4) muscarinic receptor agonist. This subtype selectivity profile has been claimed to explain the limited classical cholinomimetic side effects, particularly gastrointestinal, seen with xanomeline in animals. However, in both healthy volunteers and Alzheimer's patients many of these side effects have been reported for xanomeline and in the patient population this led to a >50% discontinuation rate. Clearly, the preclinical studies have not been able to predict this adverse profile of xanomeline, and this suggests that either xanomeline is not as subtype selective as predicted from preclinical research or that there are differences between humans and animals with regard to muscarinic receptors. Nevertheless, in Alzheimer's patients xanomeline dose-dependently improves aspects of behavioral disturbance and social behavior including a reduction in hallucinations, agitation, delusions, vocal outbursts and suspiciousness. The effects on cognition are not as robust and mainly seen at the highest doses tested. These effects in Alzheimer's patients have given impetus to the suggestion that muscarinic agonists have potential antipsychotic effects. The current review assesses the antipsychotic profile of xanomeline within the framework of the limited clinical studies with cholinergic agents in man, and the preclinical research on xanomeline using various models commonly used for the assessment of new antipsychotic drugs. In general, xanomeline has an antipsychotic-like profile in various dopamine models of psychosis and this agrees with the known interactions between the cholinergic and dopaminergic systems in the brain. Moreover, current data suggests that the actions of xanomeline at the M(4) muscarinic receptor subtype might mediate its antidopaminergic effects. Particularly intriguing are studies showing that xanomeline, even after acute administration, selectively inhibits the firing of mesolimbic dopamine cells relative to dopamine cell bodies projecting to the striatum. This data suggest that xanomeline would have a faster onset of action compared to current antipsychotics and would not induce extrapyramidal side effects. The preclinical data on the whole are promising for an antipsychotic-like profile. If in a new formulation (i.e., transdermal) xanomeline has less adverse effects, this drug may be valuable in the treatment of patients with psychosis.
Collapse
Affiliation(s)
- Naheed R Mirza
- Department of Pharmacology, NeuroSearch A/S, 93 Pederstrupvej, Ballerup, Denmark.
| | | | | |
Collapse
|
9
|
Maurer HH. Liquid chromatography-mass spectrometry in forensic and clinical toxicology. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 1998; 713:3-25. [PMID: 9700550 DOI: 10.1016/s0378-4347(97)00514-8] [Citation(s) in RCA: 160] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
This paper reviews liquid chromatographic-mass spectrometric (LC-MS) procedures for the identification and/or quantification of drugs of abuse, therapeutic drugs, poisons and/or their metabolites in biosamples (whole blood, plasma, serum, urine, cerebrospinal fluid, vitreous humor, liver or hair) of humans or animals (cattle, dog, horse, mouse, pig or rat). Papers published from 1995 to early 1997, which are relevant to clinical toxicology, forensic toxicology, doping control or drug metabolism and pharmacokinetics, were taken into consideration. They cover the following analytes: amphetamines, cocaine, lysergide (LSD), opiates, anabolics, antihypertensives, benzodiazepines, cardiac glycosides, corticosteroids, immunosuppressants, neuroleptics, non-steroidal anti-inflammatory drugs (NSAID), opioids, quaternary amines, xanthins, biogenic poisons such as aconitines, aflatoxins, amanitins and nicotine, and pesticides. LC-MS interface types, mass spectral detection modes, sample preparation procedures and chromatographic systems applied in the reviewed papers are discussed. Basic information about the biosample assayed, work-up, LC column, mobile phase, interface type, mass spectral detection mode, and validation data of each procedure is summarized in tables. Examples of typical LC-MS applications are presented.
Collapse
Affiliation(s)
- H H Maurer
- Department of Toxicology, University of Saarland, Homburg (Saar), Germany
| |
Collapse
|
10
|
Simpson RC. Quantitative determination of a nonpeptide antithrombotic in dog plasma by microbore high-performance liquid chromatography-tandem mass spectrometry utilizing pneumatically assisted electrospray ionization. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 1996; 7:1238-1244. [PMID: 24203156 DOI: 10.1016/s1044-0305(96)00112-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/12/1996] [Revised: 06/25/1996] [Accepted: 07/06/1996] [Indexed: 06/02/2023]
Abstract
A method has been developed and is described for the quantitative determination of a nonpeptide antithrombotic in dog plasma. The assay employs reversed phase microbore high-performance liquid chromatography in conjunction with tandem mass spectrometry utilizing pneumatically assisted electrospray ionization. The analyte and internal standard are isolated from the plasma matrix by solid-phase extraction. The mass spectrometer is operated in the positive ion multiple reaction monitoring mode and is set to detect the presence of a precursor-product ion pair for both the analyte and internal standard to generate product ion chromatograms for both species. The analyte is quantified by using weighted least-squares regression of the peak height ratio of drug:internal standard. The method provides linear response for plasma concentrations ranging from 5 ng/mL (25 pg on-column) to 2500 ng/mL. Statistical evaluation and examples of authentic sample assays are also presented.
Collapse
Affiliation(s)
- R C Simpson
- Department of Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA
| |
Collapse
|